XBiotech (XBIT) – Corporate News
-
XBiotech (XBIT) Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
-
XBiotech (XBIT) Announces FDA Authorization of Phase II Study for Natrunix
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to XBIT Stock Lookup